Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis (Q37721156)

22 August 2017

0 references

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis (English)

1 reference

22 August 2017

0 references

0 references

1 reference

1 reference

4

A M Gori

1 reference

22 August 2017

1

F Sofi

1 reference

22 August 2017

R Marcucci

3

0 references

Betti Giusti

object named as

B Giusti

series ordinal

2

0 references

author name string

R Abbate

series ordinal

5

1 reference

22 August 2017

G F Gensini

series ordinal

6

1 reference

22 August 2017

publication date

30 March 2010

1 reference

The Pharmacogenomics Journal

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

199-206

1 reference

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Clopidogrel, genetics, and drug responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

Pharmacokinetics of clopidogrel in patients with stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2010.21

21 January 2018

Identifiers

DOI

10.1038/TPJ.2010.21

1 reference

22 August 2017

1 reference